Rozanolixizumab for Generalized Myasthenia Gravis in Chinese Adults
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests an investigational drug called rozanolixizumab for Chinese adults with generalized myasthenia gravis who have a specific antibody (AChR or MuSK) and symptoms that still affect daily activities. It aims to see if the drug helps improve muscle strength and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have generalized myasthenia gravis (gMG) and a positive test for AChR or MuSK antibodies.
- You are 18 years or older and weigh at least 35 kg (about 77 lbs).
- Your symptoms affect daily life (MG-ADL score at least 3 from non-eye symptoms and QMG score at least 11).
- You are not severely weak in throat or breathing muscles (no crisis or impending crisis).
- You haven't taken rozanolixizumab before and have no active serious infection or untreated tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This trial tests whether ravulizumab, a medication that blocks part of the immune system, can improve muscle weakness and fatigue in people with generalized myasthenia gravis (gMG). The study focuses on Chinese adults who have moderate-to-severe MG symptoms despite current treatments.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.